Early Improvement and Marriage Are Determinants of the 12-Month Treatment Outcome of Paroxetine in Outpatients with Panic Disorder

키워드

참고문헌 (43)

1. Kessler RC, "The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication", Arch Gen Psychiatry, 63, pp.415~424 (2006)
2. Carlbring P, "12-month prevalence of panic disorder with or without agoraphobia in the Swedish general population", Soc Psychiatry Psychiatr Epidemiol, 37, pp.207~211 (2002)
3. Crowe RR, "A family study of panic disorder", Arch Gen Psychiatry, 40, pp.1065~1069 (1983)
4. Harris EL, "Family study of agoraphobia. Report of a pilot study", Arch Gen Psychiatry, 40, pp.1061~1064 (1983)
5. Skre I, "A twin study of DSM-III-R anxiety disorders", Acta Psychiatr Scand, 88, pp.85~92 (1993)
6. Hettema JM, "A review and meta-analysis of the genetic epidemiology of anxiety disorders", Am J Psychiatry, 158, pp.1568~1578 (2001)
7. Domschke K, "Association of the functional-1019C", G 5-HT1A polymorphism with prefrontal cortex and amygdala activation measured with 3 T fMRI in panic disorder, 2006, pp.9, 349~355
8. Stahl SM, "Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents", J Clin Psychiatry, 63, pp.854~855 (2002)
9. Gross C, "Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult", Nature, 416, pp.396~400 (2002)
10. Heils A, "Allelic variation of human serotonin transporter gene expression", J Neurochem, 66, pp.2621~2624 (1996)
11. Deckert J, "Functional promoter polymorphism of the human serotonin transporter : lack of association with panic disorder", Psychiatr Genet, 7, pp.45~47 (1997)
12. Hamilton SP, "Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder", Psychiatr Genet, 9, pp.1~6 (1999)
13. Ishiguro H, "An association study between a transcriptional polymorphism in the serotonin transporter gene and panic disorder in a Japanese population", Psychiatry Clin Neurosci, 51, pp.333~335 (1997)
14. Olesen OF, "The short", long polymorphism in the serotonin transporter gene promoter is not associated with panic disorder in a Scandinavian sample, 2005, pp.15, 159~
15. Blaya C, "Lack of association between the serotonin transporter promoter polymorphism(5-HTTLPR)and panic disorder : a systematic review and meta-analysis", Behav Brain Funct, 3, pp.41~ (2007)
16. Le François B, "Transcriptional regulation at a HTR1A polymorphism associated with mental illness", Neuropharmacology, 55, pp.977~985 (2008)
17. Freitag CM, "Interaction of serotonergic and noradrenergic gene variants in panic disorder", Psychiatr Genet, 16, pp.59~65 (2006)
18. Rothe C, "Association of a functional 1019C＞G 5-HT1A receptor gene polymorphism with panic disorder with agoraphobia", Int J Neuropsychopharmacol, 7, pp.189~192 (2004)
19. Faravelli C, "Prevalence of traumatic early life events in 31 agoraphobic patients with panic attacks", Am J Psychiatry, 142, pp.1493~1494 (1985)
20. Faravelli C, "Recent life events and panic disorder", Am J Psychiatry, 146, pp.622~626 (1989)
21. Chou KL, "Panic disorder in older adults : evidence from the national epidemiologic survey on alcohol and related conditions", Int J Geriatr Psychiatry, 25, pp.822~832 (2010)
22. Marcaurelle R, "Marital predictors of symptom severity in panic disorder with agoraphobia", J Anxiety Disord, 19, pp.211~232 (2005)
23. Manuck SB, "The socio-economic status of communities predicts variation in brain serotonergic responsivity", Psychol Med, 35, pp.519~528 (2005)
24. Choe AY, "Serotonergic genes(5-HTT and HTR1A)and separation life events : gene-by-environment interaction for panic disorder", Neuropsychobiology, 67, pp.192~200 (2013)
25. Mojtabai R, "Long-term effects of mental disorders on educational attainment in the National Comorbidity Survey ten-year follow-up", Soc Psychiatry Psychiatr Epidemiol, 50, pp.1577~1591 (2015)
26. Bakhshaie J, "Cigarette smoking and the onset and persistence of panic attacks during mid-adulthood in the United States: 1994-2005", J Clin Psychiatry, 77, pp.e21~e24 (2016)
27. Kim B, "White matter microstructural changes are associated with alcohol use in patients with panic disorder", J Affect Disord, 199, pp.65~72 (2016)
28. Perna G, "Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene", Neuropsychopharmacology, 30, pp.2230~2235 (2005)
29. Yevtushenko OO, "Early response to selective serotonin reuptake inhibitors in panic disorder is associated with a functional 5-HT1A receptor gene polymorphism", J Affect Disord, 123, pp.308~311 (2010)
30. Szegedi A, "Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder : a meta-analysis including 6562 patients", J Clin Psychiatry, 70, pp.344~353 (2009)
31. Cusin C, "Early symptomatic worsening during treatment with fluoxetine in major depressive disorder : prevalence and implications", J Clin Psychiatry, 68, pp.52~57 (2007)
32. Kato M, "Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs", Transl Psychiatry, 5, pp.e513~ (2015)
33. Guy W, "ECDEU assessment manual for psychopharmacology", pp.616~ (1976), U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs
34. Aoki A, "Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder", Neuropsychiatr Dis Treat, 10, pp.1793~1798 (2014)
35. Ishiguro S, "Determinants of pharmacodynamic trajectory of the therapeutic response to paroxetine in Japanese patients with panic disorder", Eur J Clin Pharmacol, 67, pp.1213~1221 (2011)
36. Han KM, "Mental health service use in adults with suicidal ideation within a nationally representative sample of the Korean population", J Affect Disord, 193, pp.339~347 (2016)
37. Lesch KP, "Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region", Science, 274, pp.1527~1531 (1996)
38. 오강섭, "Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study", Clinical Psychopharmacology and Neuroscience, 14(2), pp.161~167 (2016), 대한정신약물학회
39. Mavissakalian MR, "Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia", Arch Gen Psychiatry, 56, pp.821~827 (1999)
40. Kwan-Woo Choi, "Long-term Escitalopram Treatment in Korean Patients with Panic Disorder: A Prospective, Naturalistic, Open-label, Multicenter Trial", Clinical Psychopharmacology and Neuroscience, 10(1), pp.44~48 (2012), 대한정신약물학회
41. Bandelow B, "Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale", Int Clin Psychopharmacol, 10, pp.73~81 (1995)
42. Nardi AE, "A randomized, naturalistic, parallelgroup study for the long-term treatment of panic disorder with clonazepam or paroxetine", J Clin Psychopharmacol, 32, pp.120~126 (2012)
43. Uguz F, "Low-dose imipramine for treatment of panic disorder during pregnancy : a retrospective chart review", J Clin Psychopharmacol, 34, pp.513~515 (2014)

관련 논문AI추천